Mei et al. (2023) observed a 65% response rate within 43 low-risk MDS patients who received a combination of EPO (10,000 IU/day), all-trans retinoic acid (25 mg/m2/day), and testosterone undecanoate (80 mg twice daily). The gene discussed is EPO; the disease is myelodysplastic syndrome.